EP 3328382 A4 20181219 - BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION
Title (en)
BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION
Title (de)
GEGEN MYCOBAKTERIELLE INFEKTIONEN NÜTZLICHE, BENZYLAMINHALTIGE HETEROCYCLISCHE VERBINDUNGEN
Title (fr)
COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DE LA BENZYLAMINE ET COMPOSITIONS UTILES CONTRE UNE INFECTION MYCOBACTÉRIENNE
Publication
Application
Priority
- US 201562220192 P 20150917
- US 2016052558 W 20160919
Abstract (en)
[origin: WO2017049321A1] Described herein are compounds and compositions, and methods of making and their use as effective agents against mycobacterial infections.
IPC 8 full level
A61K 31/437 (2006.01); A61P 31/00 (2006.01); C07D 235/00 (2006.01); C07D 239/26 (2006.01)
CPC (source: EP IL KR US)
A61K 31/4188 (2013.01 - IL); A61K 31/429 (2013.01 - IL KR); A61K 31/437 (2013.01 - KR); A61P 3/04 (2017.12 - IL); A61P 3/10 (2017.12 - IL); A61P 31/00 (2017.12 - EP US); A61P 31/06 (2017.12 - KR); C07D 471/04 (2013.01 - EP IL KR US); C07D 513/04 (2013.01 - EP IL KR US)
Citation (search report)
- [XI] WO 2014015167 A2 20140123 - MORASKI GARRETT [US], et al
- [XI] WO 2015014993 A2 20150205 - PASTEUR INSTITUT KOREA [KR], et al
- [X] US 2014088080 A1 20140327 - KOGA YUJI [JP], et al
- [X] GARRETT C. MORASKI ET AL: "Advent of Imidazo[1,2- a ]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity", ACS MEDICINAL CHEMISTRY LETTERS, vol. 2, no. 6, 9 June 2011 (2011-06-09), pages 466 - 470, XP055522375, ISSN: 1948-5875, DOI: 10.1021/ml200036r
- [X] GARRETT C. MORASKI ET AL: "Advancement of Imidazo[1,2- a ]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 7, 11 July 2013 (2013-07-11), pages 675 - 679, XP055329677, ISSN: 1948-5875, DOI: 10.1021/ml400088y
- [X] SUNHEE KANG ET AL: "Lead Optimization of a Novel Series of Imidazo[1,2- a ]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 12, 26 June 2014 (2014-06-26), pages 5293 - 5305, XP055329580, ISSN: 0022-2623, DOI: 10.1021/jm5003606
- See references of WO 2017049321A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017049321 A1 20170323; AU 2016324598 A1 20180315; AU 2021203931 A1 20210708; BR 112018005208 A2 20181002; BR 112018005208 B1 20231212; CA 2998375 A1 20170323; CL 2018000688 A1 20181116; CN 108348510 A 20180731; CN 108348510 B 20220104; EP 3328382 A1 20180606; EP 3328382 A4 20181219; HK 1252225 A1 20190524; IL 257743 A 20180430; IL 257743 B 20220801; JP 2018532723 A 20181108; JP 7055378 B2 20220418; KR 20180053386 A 20180521; MX 2018003294 A 20190425; MX 2021000189 A 20210325; PE 20181352 A1 20180822; RU 2018111768 A 20191017; RU 2018111768 A3 20200220; US 10919888 B2 20210216; US 11820767 B2 20231121; US 2018265506 A1 20180920; US 2021198254 A1 20210701; ZA 201802323 B 20190130
DOCDB simple family (application)
US 2016052558 W 20160919; AU 2016324598 A 20160919; AU 2021203931 A 20210614; BR 112018005208 A 20160919; CA 2998375 A 20160919; CL 2018000688 A 20180315; CN 201680063042 A 20160919; EP 16847573 A 20160919; HK 18111462 A 20180906; IL 25774318 A 20180226; JP 2018514425 A 20160919; KR 20187010743 A 20160919; MX 2018003294 A 20160919; MX 2021000189 A 20180315; PE 2018000402 A 20160919; RU 2018111768 A 20160919; US 201615760939 A 20160919; US 202017135927 A 20201228; ZA 201802323 A 20180410